Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- Drug: Novo Rapid
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 23
- Registration Number
- NCT04698018
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
🇭🇰Phase 1 Clinical Trial Centre, Shatin, New Territories, Hong Kong
Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol
- Conditions
- Haemophilia A
- Interventions
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 50
- Registration Number
- NCT04682145
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Søborg, Denmark
A Study Investigating the Distribution and Metabolism of Three 14C-labeled Radioactive Study Compounds
Phase 1
Completed
- Conditions
- Type 2 DiabetesHealthy Volunteers
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 18
- Registration Number
- NCT04676906
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands
A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in Italy
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Insulin degludec and liraglutide (IDegLira)
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 359
- Registration Number
- NCT04666987
- Locations
- 🇮🇹
A.O. SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
🇮🇹Ospedale Camberlingo, Francavilla Fontana, Italy
🇮🇹Ospedale Santa Maria Goretti - UOD Diabetologia, Latina, LT, Italy
A Study to Look at How Safe Insulin NNC0471-0119 is and How it Works in People With Type 1 Diabetes Mellitus
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2023-01-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 48
- Registration Number
- NCT04655690
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
A Study Investigating the Clinical Parameters Associated With the Use of Ryzodeg® (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in South Korea
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 200
- Registration Number
- NCT04656106
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Suwon-si, Gyeonggi-do, Korea, Republic of
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.
Phase 2
Completed
- Conditions
- Chronic Kidney DiseaseInflammationCardiovascular Risk
- Interventions
- Drug: Placebo (ziltivekimab)
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2021-10-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT04626505
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Ehime, Japan
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 194
- Registration Number
- NCT04601753
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Malmö, Sweden
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 145
- Registration Number
- NCT04601740
- Locations
- 🇳🇱
Master Centre Netherlands, Alphen A/d Rijn, Netherlands
A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes
Phase 3
Active, not recruiting
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Placebo (semaglutide)
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 132
- Registration Number
- NCT04596631
- Locations
- 🇮🇱
Rambam Medical Center Children A Dept., Haifa, Israel
🇱🇧Chronic Care Center, Hazmieh, Lebanon
🇲🇾University Malaya Medical Centre, Kuala Lumpur, Malaysia
© Copyright 2025. All Rights Reserved by MedPath